MoonLake Immunotherapeutics (MLTX) Tops Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts MLTX Hot Sheet
Join SI Premium – FREE
MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q2 EPS of ($0.84), $0.09 better than the analyst estimate of ($0.93).
For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- DelphX launches private placement targeting up to C$50,000
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
